MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

SCORE2-HF

  • Home
  • SCORE2-HF
Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment
Posted inCardiology Internal Medicine news

Predicting Heart Failure Before It Starts: The New SCORE2-HF Model and Clinical Consensus for Cardiovascular Risk Assessment

Posted by By MedXY 03/11/2026
This article details the SCORE2-HF risk model, a newly validated tool designed to estimate 10-year and 30-year heart failure risks in asymptomatic individuals, enabling earlier intervention and personalized cardiovascular care across diverse European risk regions.
Read More
  • Enhancing Post-Stroke Physical Activity Through Telehealth and Wearable Technology: A Feasibility Randomised Controlled Trial
  • Advancing Dental Education: Repair Versus Replacement of Defective Composite Restorations in Canadian Dental Schools
  • Immunogenicity and Safety of Fractional 17DD Yellow Fever Vaccine Doses in Young Children: Evidence from a Phase 4 Randomised Trial in Uganda and Broader Context
  • Enhancing Prehospital Pediatric Ventilation Quality with Real-Time Feedback Devices: Insights from a Randomized Study
  • Nerandomilast Shows Promise in Slowing Progressive Pulmonary Fibrosis in Autoimmune Disease: Insights from the FIBRONEER-ILD Trial
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top